title: A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. The Protocol 043 Study Group.
abstract: METHODS
  Zidovudine has been shown to be an effective antiretroviral treatment in adults with human immunodeficiency virus (HIV) infection. We examined the safety of zidovudine and the tolerance of and therapeutic response to the drug in 88 children with advanced HIV disease. During a 24-week outpatient trial, zidovudine (180 mg per square meter of body-surface area per dose) was given by mouth every six hours and serial measurements were made of clinical, immunologic, and virologic indexes. Children who completed 24 weeks of treatment were permitted to continue receiving zidovudine.
  
  
  RESULTS
  Of the 88 children (mean age, 3.9 years; range, 4 months to 11 years), 61 completed the initial 24-week trial, and 49 continued to receive zidovudine for up to 90 weeks (median follow-up, 56 weeks). The patients generally tolerated zidovudine well. One or more episodes of hematologic toxicity occurred in 54 children (61 percent)--anemia (hemoglobin level, less than 75 g per liter) in 23 children (26 percent) and neutropenia (neutrophil count, less than 0.75 x 10(9) per liter) in 42 (48 percent). Many of these abnormalities resolved spontaneously, but 30 children required transfusions or a modification of the dose of zidovudine. Only three children had to stop receiving the drug because of hematologic toxicity. Kaplan-Meier analysis demonstrated that the probability of survival was 0.89 after 24 weeks and 0.79 after 52 weeks. There was marked improvement in weight gain, cognitive function (mainly in children less than 3 years old), serum and cerebrospinal fluid concentrations of p24 antigen, and the proportion of cerebrospinal fluid cultures negative for HIV. CD4+ lymphocyte counts (mean at base line, 0.263 x 10(9) per liter) improved during the first 12 weeks, although the improvement was not sustained through the 24th week.
  
  
  CONCLUSIONS
  Zidovudine in a dose of 180 mg per square meter every six hours can be safely administered to children with advanced HIV disease. The resultant clinical, immunologic, and virologic improvements in children are similar to those reported with zidovudine in adults.
authors.affiliation: Department of Pediatrics, Duke University School of Medicine, Durham, N.C. 27710.
authors.forename: R E
authors.initials: RE
authors.lastname: McKinney
authors.forename: M A
authors.initials: MA
authors.lastname: Maha
authors.forename: E M
authors.initials: EM
authors.lastname: Connor
authors.forename: J
authors.initials: J
authors.lastname: Feinberg
authors.forename: G B
authors.initials: GB
authors.lastname: Scott
authors.forename: M
authors.initials: M
authors.lastname: Wulfsohn
authors.forename: K
authors.initials: K
authors.lastname: McIntosh
authors.forename: W
authors.initials: W
authors.lastname: Borkowsky
authors.forename: J F
authors.initials: JF
authors.lastname: Modlin
authors.forename: P
authors.initials: P
authors.lastname: Weintrub
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy; D000284:Administration, Oral; D015496:CD4-Positive T-Lymphocytes; D002648:Child; D002675:Child, Preschool; D003071:Cognition / Q000187:drug effects; D004341:Drug Evaluation; D004361:Drug Tolerance; D005500:Follow-Up Studies; D015683:Gene Products, gag / Q000032:analysis; D006128:Growth / Q000187:drug effects; D016655:HIV Core Protein p24; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007223:Infant; D015337:Multicenter Studies as Topic; D009894:Opportunistic Infections / Q000150:complications; D014758:Viral Core Proteins / Q000032:analysis; D015430:Weight Gain / Q000187:drug effects; D015215:Zidovudine / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D015683:Gene Products, gag; D016655:HIV Core Protein p24; D014758:Viral Core Proteins; D015215:Zidovudine